Efficacy of Upadacitinib vs Dupilumab Treatment for Moderate‑to‑Severe Atopic Dermatitis: Analysis of Time Spent in Response State From the Level Up Study

Le résumé fourni par la source

Introduction & Objectives: Upadacitinib (UPA), a selective oral Janus kinase (JAK) inhibitor, and dupilumab (DUPI), a monoclonal antibody targeting interleukin-4Rα, are both treatments approved for patients with moderate-to-severe Atopic Dermatitis (AD). Results from a phase 3b/4 trial (Level Up NCT05601882) indicated that UPA was superior to DUPI in simultaneously achieving the stringent endpoints of Eczema Area and Severity Index (EASI) improvement of ≥90% from baseline (EASI 90) and a Worst Pruritus Numerical Rating Scale score of 0/1 (WP-NRS 0/1) at Week 16. In this post-hoc analysis, we analyzed the median time (days) spent in response states based on EASI 90 and/or WP-NRS 0/1 in patients either receiving UPA or DUPI over a 16-week period. Materials & Methods: The Level Up study was a phase 3b/4 head-to-head global, randomized, open-label, efficacy assessor blinded, multicenter study comparing UPA vs DUPI in adolescents and adults with moderate-to-severe AD. Patients were randomized to UPA 15 mg or DUPI per its label for 16 weeks of treatment. Patients on UPA 15 mg were dose-escalated to 30 mg starting at Week 4 if they had a

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.